Developer of a neuroprotective small molecule drug intended for the treatment of Huntington disease (HD) and Amyotrophic Lateral Sclerosis (ALS). The company targets neurodegenerative disorders, enabling healthcare professionals to avoid characteristic misfolded proteins that aggregate and induce neuronal toxicity and death.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
1. Accelerator/Incubator | Completed | Startup |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Niva Segev Amzaleg | Chief Scientific Officer | ||
Brent Stockwell Ph.D | Founder & Advisor |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
FutuRx | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |